Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature ...

Bio-Hermes-002 Bio-Hermes-002 is the unique, observational platform study that compares blood-based and digital biomarkers ...

Cronometer, a leader in nutrition and health tracking, is proud to announce the integration of Continuous Glucose Monitors (CGMs) with its innovative platform. This feature provides users with the ...

Scientists have developed a lipid nanoparticle system that enables mRNA to cross the blood-brain barrier, a long-standing challenge in n.

Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today the ...

Several large Massachusetts employers have filed annual reports with federal securities regulators that are notable for ...

The Parnassus Value Equity Fund returned -1.48% (net) for Q4 2024, outperforming the Russell 1000 Value Index’s -1.98%. Click ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...